The Europe Photoacoustic Imaging Market would witness market growth of 9.0% CAGR during the forecast period (2023-2030).
Breast cancer imaging is a possible significant clinical use for PAI in oncology. The most sophisticated PAI method for clinical usage is breast imaging, which has advantages, including oxygen saturation mapping and non-contrast imaging of the neovasculature surrounding a tumour. Unlike X-ray imaging, PAI can identify cancers in radiologically dense breast tissue without uncomfortable breast compression. Because it makes it possible to identify cancer, neurological issues, and vascular diseases accurately and quickly, this approach has become increasingly popular in recent years.
In preclinical studies, PAI is an effective non-invasive, non-ionizing method for characterizing tiny animals?like mice or rats?without damaging them. Small-animal models of brain damage and disease processes, particularly those requiring research on vascular anatomy or function, including epilepsy, stroke, and traumatic brain injury, can be characterized. The extensive use of PAI in research platforms to examine the mechanisms underlying human disease and create novel treatments is anticipated to promote market expansion.
Research from the UK government titled "Future of an ageing population" predicts that by 2040, one in seven individuals in the UK will be over the age of 75. An additional 1.42 million families with a head of household who is 85 years of age or older are anticipated to exist by 2037, representing a 161% increase in that time. Over 5.5 million more people?or an increase of 26%?will be added to the working-age population between the ages of 50 and the state pension age (SPA) between 2012 and 2050. Due to the increased probability of conditions that may require photoacoustic imaging among the aging population in European nations, growth prospects are expected to be favourable.
The Germany market dominated the Europe Photoacoustic Imaging Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $11,416.9 Thousands by 2030. The UK market is estimated to witness a CAGR of 8% during (2023 - 2030). Additionally, The France market would register a CAGR of 9.8% during (2023 - 2030).
Based on Product, the market is segmented into Imaging Systems, Transducer, Lasers, and Others. Based on End User, the market is segmented into Diagnostic Imaging Centers, Hospitals, and Others. Based on Type, the market is segmented into Microscopy, and Tomography. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Advantest Corporation, Prexion Corporation, Seno Medical Instruments, Inc., illumiSonics, Inc., OPOTEK LLC, EKSLPA (EKSMA Group), Verasonics, Inc., Photosound Technologies, Inc., iThera Medical GmbH.
Scope of the Study
Market Segments covered in the Report:
By Product

  • Imaging Systems
  • Transducer
  • Lasers
  • Others


By End User

  • Diagnostic Imaging Centers
  • Hospitals
  • Others


By Type

  • Microscopy
  • Tomography


By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Companies Profiled

  • Fujifilm Holdings Corporation
  • Advantest Corporation
  • Prexion Corporation
  • Seno Medical Instruments, Inc.
  • illumiSonics, Inc.
  • OPOTEK LLC, EKSLPA (EKSMA Group)
  • Verasonics, Inc.
  • Photosound Technologies, Inc.
  • iThera Medical GmbH


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free